• Home
• Medications
• ACE Inhibitors and ARBs: What You Need to Know About Interactions and Cross-Reactivity

ACE Inhibitors and ARBs: What You Need to Know About Interactions and Cross-Reactivity

Many people take ACE inhibitors or ARBs to manage high blood pressure, heart failure, or kidney disease. But if you're on one of these drugs, you might be wondering: Can I take both together? What happens if I switch from one to the other? Are there hidden risks most doctors don’t talk about?

The short answer: Combining ACE inhibitors and ARBs is dangerous for most people. Even though they both target the same system in your body, mixing them doesn’t give you better results-it just ups your risk of serious side effects. And many patients don’t realize they’re being put at risk until it’s too late.

How ACE Inhibitors and ARBs Work (And Why They’re Not the Same)

Both ACE inhibitors and ARBs are designed to relax blood vessels and lower blood pressure by blocking parts of the renin-angiotensin system (RAS). But they do it in completely different ways.

ACE inhibitors like lisinopril, enalapril, and ramipril stop your body from making angiotensin II, a chemical that tightens blood vessels and raises blood pressure. They work by blocking the enzyme that turns angiotensin I into angiotensin II.

ARBs like losartan, valsartan, and irbesartan don’t stop angiotensin II from being made. Instead, they block the receptors where angiotensin II tries to bind. Think of it like a lock and key: ACE inhibitors reduce the number of keys being made. ARBs keep the locks from opening-even if the keys are still around.

This difference matters. Because ACE inhibitors cause a buildup of bradykinin-a side effect of enzyme inhibition-they often trigger a dry, hacking cough in 10-15% of users. ARBs rarely cause this because they don’t affect bradykinin. That’s why many patients switch from an ACE inhibitor to an ARB: not because the blood pressure control is better, but because the cough is unbearable.

Another key difference: ACE inhibitors have stronger proof of reducing death in heart failure patients. Studies show a 23% lower risk of dying compared to 15% with ARBs. That’s why guidelines still recommend ACE inhibitors as first-line for heart failure with reduced pumping ability.

Why Combining Them Is a Bad Idea

It makes sense on paper. If one drug blocks angiotensin II production, and the other blocks its action, shouldn’t two be better than one?

Reality says no.

The ONTARGET trial in 2008, which followed over 25,000 high-risk patients, found that combining ramipril (an ACE inhibitor) with telmisartan (an ARB) didn’t lower heart attacks, strokes, or deaths. But it did double the risk of dangerously high potassium levels (hyperkalemia) and nearly doubled the chance of acute kidney injury.

Here’s what that looks like in real life:

• Hyperkalemia went from 2.5% on ramipril alone to 5.5% on the combo.
• Patients on the combo were more likely to need dialysis-2.3% vs. 1.0%.
• There was no improvement in survival, heart attack rates, or hospital stays.

The FDA and major heart associations (AHA, ACC, ESC) all agree: don’t combine ACE inhibitors and ARBs. The 2023 AHA guidelines call it a practice to avoid outside of clinical trials. The Cleveland Clinic’s 2023 recommendations bluntly state: “I try not to combine ACE inhibitors with ARBs.”

Even small doses don’t fix the problem. A 2023 survey of 317 U.S. primary care doctors found that 89% had stopped prescribing the combo after the 2018 VA NEPHRON-D trial showed a 27% increase in serious side effects with no benefit.

When Is It Ever Okay to Combine Them?

There are exceptions-but they’re rare.

Some nephrologists may consider adding an ARB to an ACE inhibitor for patients with non-diabetic kidney disease who have proteinuria over 1 gram per day, and who haven’t responded to maximum ACE inhibitor doses. But even then, it’s not a green light.

Dr. Srinivasan Beddhu from the University of Utah says this approach might help reduce proteinuria in rare cases. But he stresses it requires weekly blood tests for potassium and kidney function. Patients need to be monitored like they’re in a hospital, not a regular clinic.

One Reddit thread from March 2024 shared stories from medical residents who saw 78% of patients on combo therapy develop high potassium levels or sudden kidney decline. In contrast, a few patients with rare kidney conditions like focal segmental glomerulosclerosis did report big drops in proteinuria-but all required intense monitoring.

Bottom line: If you’re not in a clinical trial or under the care of a kidney specialist who checks your labs every week, you should not be on both drugs.

Switching Between ACE Inhibitors and ARBs

If you’re having side effects from an ACE inhibitor-like a persistent cough or swelling in your face (angioedema)-switching to an ARB is often the right move.

But don’t just stop one and start the other the next day.

There’s a risk of additive effects. Your blood pressure could drop too low. Your kidneys could shut down. Potassium could spike.

Guidelines recommend a 4-week washout period between switching. That means stopping the ACE inhibitor, waiting a month, then starting the ARB. In practice, only about 42% of doctors follow this rule, according to a 2022 JAMA Internal Medicine study.

If you’re switching, here’s what you should do:

1. Ask your doctor for a clear plan-don’t self-switch.
2. Get blood tests before and 1-2 weeks after the switch: potassium and creatinine.
3. Watch for dizziness, fainting, or reduced urine output.
4. Don’t start any new supplements (like potassium salts or salt substitutes) without checking with your doctor.

Many patients think switching is safe because both drugs “do the same thing.” But the body reacts differently to each. Even if you’ve been on lisinopril for years, your system still needs time to reset.

Side Effects You Can’t Ignore

Both drugs can raise potassium and hurt kidney function, especially in older adults, diabetics, or people with existing kidney disease.

Here’s what to watch for:

• High potassium (hyperkalemia): Can cause irregular heartbeat, muscle weakness, or cardiac arrest. Normal potassium is 3.5-5.0 mmol/L. Levels above 5.5 require urgent action.
• Acute kidney injury: A sudden drop in kidney function. Often shows up as rising creatinine (more than 30% increase from baseline).
• Low blood pressure: Dizziness when standing, fatigue, blurred vision.
• Angioedema: Swelling of lips, tongue, throat. This is a medical emergency. It’s rare (0.1-0.7% with ACE inhibitors) but can be fatal if untreated.

Patients on these drugs should have blood tests every 3 months once stable. If you’re newly started, get tested after 1-2 weeks.

And here’s something many don’t know: ACE inhibitors can cause angioedema even after years of use. A 65-year-old patient on lisinopril for 8 years might suddenly develop swelling-not because they changed their dose, but because their body finally reacted.

What to Do Instead of Combining Them

If your blood pressure isn’t controlled on one RAS blocker, or your proteinuria is still high, there are safer options.

Instead of adding an ARB to your ACE inhibitor:

• Try adding a low-dose spironolactone (12.5 mg daily). It’s a mineralocorticoid blocker that reduces proteinuria by 30-40% with fewer kidney risks.
• Use a calcium channel blocker like amlodipine for extra blood pressure control.
• For heart failure, consider an ARNI (sacubitril/valsartan), which combines an ARB with a neprilysin inhibitor. It’s proven to reduce death better than ACE inhibitors alone.
• For kidney protection, focus on tight blood sugar control (if diabetic), sodium restriction, and avoiding NSAIDs like ibuprofen.

These alternatives have better safety profiles and real-world data backing them. The goal isn’t to hit the lowest possible blood pressure-it’s to avoid hospitalization, dialysis, or death.

What’s Next? New Drugs and Changing Guidelines

The future of RAS blockade isn’t about combining old drugs-it’s about replacing them with smarter ones.

The FDA approved a fixed-dose combo of perindopril and indapamide in Europe for heart failure, but it’s not approved for hypertension in the U.S. And it’s not an ACE-ARB combo-it’s an ACE inhibitor with a diuretic, which is much safer.

The FINE-REWIND trial (2024-2028) is testing whether ultra-low doses of both an ACE inhibitor and ARB might work safely in diabetic kidney disease. But results won’t be out until 2026.

Meanwhile, the use of ACE-ARB combinations is expected to drop below 1% of all RAS blocker prescriptions by 2028. The trend is clear: fewer combos, more monitoring, and better alternatives.

For now, stick with one drug. If it’s not working, talk to your doctor about alternatives-not about adding another.

Frequently Asked Questions

What to Do Next

If you’re on an ACE inhibitor or ARB, here’s what to do right now:

1. Check your current meds. Are you taking both an ACE inhibitor and an ARB? If yes, talk to your doctor immediately.
2. Look up your last blood test results. What was your potassium level? Was your creatinine stable?
3. Write down any side effects: cough, dizziness, swelling, or reduced urine output.
4. Ask your doctor: “Is there a safer way to improve my blood pressure or kidney protection without combining these drugs?”

You don’t need to take two drugs that do the same thing. You need the right one-plus the right monitoring. And that’s something you can control.